Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01538095 · ClinicalTrials.gov registry record · Phase 1

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

A Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
20
Study locations

NCT01538095: Completed Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, sponsored by National Cancer Institute (NCI).

NCT01538095 is a Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01538095, a Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
20
Study locations

Study Summary

This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system tumors. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.

Conditions Studied

Solid Neoplasm Central Nervous System Neoplasm

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
  • OTHER Pharmacological Study
  • BIOLOGICAL Trebananib

Study Locations (20)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Childrens Oncology Group - Philadelphia
  • Children's Hospital of Pittsburgh of UPMC - Pittsburgh

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham

California

  • Children's Hospital of Orange County - Orange
  • UCSF Medical Center-Parnassus - San Francisco

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Children's Healthcare of Atlanta - Egleston - Atlanta

Illinois

  • Lurie Children's Hospital-Chicago - Chicago

Indiana

  • Riley Hospital for Children - Indianapolis

Michigan

  • C S Mott Children's Hospital - Ann Arbor

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2012-02
Est. Completion 2016-04
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01538095

The ClinicalTrials.gov registry entry for NCT01538095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01538095 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Pennsylvania, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT01538095 about?

NCT01538095 is a clinical study titled "Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors". This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system tumors. Trebananib may stop the growth of tumor cells by blocking blood fl...

What is the current status of trial NCT01538095?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2012-02. Estimated completion is 2016-04.

What conditions does trial NCT01538095 study?

This clinical trial studies the following conditions: Solid Neoplasm, Central Nervous System Neoplasm.

What interventions are being tested in trial NCT01538095?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Pharmacological Study (OTHER), Trebananib (BIOLOGICAL).

Who is sponsoring clinical trial NCT01538095?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01538095 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Neoplasm

All registered trials for this condition

Central Nervous System Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.